04
May
Glenmark Pharmaceuticals Limited announced the launch of Ryaltris-AZ Nasal Spray for the treatment of moderate to severe allergic rhinitis, in India. Glenmark has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India. Glenmark is the first company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasonefuroate 50 mcg + Azelastine 140 mcg.While the average cost of therapy of top 10 existing brands of the similar drug category is Rs. 365, Glenmark’s Ryaltris-AZ nasal spray has been launched at a breakthrough price of Rs.…